Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Roche Holding AG (OtherRHHVF)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cytokinetics (CYTKResearch Report) and Roche Holding AG (RHHVFResearch Report) with bullish sentiments.

Cytokinetics (CYTK)

Mizuho Securities analyst Salim Syed maintained a Buy rating on Cytokinetics today and set a price target of $80.00. The company’s shares closed last Thursday at $44.56.

According to, Syed is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.8% and a 41.9% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytokinetics with a $63.67 average price target, which is a 47.2% upside from current levels. In a report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a $60.00 price target.

See the top stocks recommended by analysts >>

Roche Holding AG (RHHVF)

In a report released today, Dominic Lunn from Credit Suisse maintained a Buy rating on Roche Holding AG, with a price target of CHF380.00. The company’s shares closed last Thursday at $301.34, close to its 52-week low of $299.01.

According to, Lunn is ranked #4341 out of 8323 analysts.

Roche Holding AG has an analyst consensus of Moderate Buy, with a price target consensus of $379.84, which is a 25.9% upside from current levels. In a report issued on January 19, Goldman Sachs also maintained a Buy rating on the stock with a CHF429.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CYTK:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More